Valuation — not yet established
No valuation for Acrivon Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($230.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Acrivon Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Apr 2024 | PIPE | $130.0M | ▮ | ▮ |
| Nov 2021 | Early Stage VC (Series B) | $100.0M | ▮ | ▮ |
| Jan 2021 | Early Stage VC | $15.5M | ▮ | ▮ |
How Acrivon Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Acrivon Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Acrivon Therapeutics raised?
- Acrivon Therapeutics has raised $230.0M in total funding across 3 recorded rounds.
- When did Acrivon Therapeutics last raise?
- Acrivon Therapeutics last raised in Apr 2024 (PIPE), raising $130.0M.